SG142116A1 - Antihypersensitive combination of valsartan and calcium channel blocker - Google Patents

Antihypersensitive combination of valsartan and calcium channel blocker

Info

Publication number
SG142116A1
SG142116A1 SG200300082-5A SG2003000825A SG142116A1 SG 142116 A1 SG142116 A1 SG 142116A1 SG 2003000825 A SG2003000825 A SG 2003000825A SG 142116 A1 SG142116 A1 SG 142116A1
Authority
SG
Singapore
Prior art keywords
hypertension
diabetic
combination
renal
valsartan
Prior art date
Application number
SG200300082-5A
Other languages
English (en)
Inventor
Gasparo Marc De
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG142116(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG142116A1 publication Critical patent/SG142116A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Hydrogenated Pyridines (AREA)
SG200300082-5A 1998-07-10 1999-07-09 Antihypersensitive combination of valsartan and calcium channel blocker SG142116A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11389398A 1998-07-10 1998-07-10

Publications (1)

Publication Number Publication Date
SG142116A1 true SG142116A1 (en) 2008-05-28

Family

ID=22352165

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200300082-5A SG142116A1 (en) 1998-07-10 1999-07-09 Antihypersensitive combination of valsartan and calcium channel blocker

Country Status (32)

Country Link
EP (3) EP1870098A3 (fr)
JP (1) JP2002520274A (fr)
KR (2) KR100550167B1 (fr)
CN (2) CN1234357C (fr)
AT (1) ATE371448T1 (fr)
AU (1) AU753486B2 (fr)
BE (1) BE2016C011I2 (fr)
BR (1) BR9912021A (fr)
CA (2) CA2336822C (fr)
CY (4) CY1107779T1 (fr)
CZ (2) CZ299429B6 (fr)
DE (2) DE69936992T2 (fr)
DK (2) DK1096932T3 (fr)
ES (2) ES2289814T3 (fr)
FR (1) FR16C0008I2 (fr)
HK (2) HK1036758A1 (fr)
HU (1) HU229383B1 (fr)
ID (1) ID27664A (fr)
IL (3) IL140665A0 (fr)
LU (2) LU91358I2 (fr)
NL (2) NL300290I2 (fr)
NO (2) NO331802B1 (fr)
NZ (2) NZ527598A (fr)
PL (1) PL194604B1 (fr)
PT (2) PT2322174E (fr)
RU (3) RU2450813C2 (fr)
SG (1) SG142116A1 (fr)
SI (2) SI2322174T1 (fr)
SK (1) SK285863B6 (fr)
TR (1) TR200100062T2 (fr)
WO (1) WO2000002543A2 (fr)
ZA (1) ZA200100232B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870098A3 (fr) 1998-07-10 2010-07-07 Novartis Ag Utilisation combinée de valsaratan et bloqueurs du canal de calcium à buts thérapeutiques
AU3043000A (en) * 1998-12-23 2000-07-31 Novartis Ag Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
PL196895B1 (pl) 1999-04-28 2008-02-29 Takeda Pharmaceutical Zastosowanie związku o aktywności antagonistycznej angiotensyny II lub jego soli do wytwarzania kompozycji farmaceutycznej do leczenia lub hamowania rozwoju retynopatii prostej lub retynopatii przed-proliferacyjnej
EP1197226B1 (fr) * 1999-07-21 2007-11-21 Takeda Pharmaceutical Company Limited Agents destines a ameliorer les troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
AU2001235363A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Mibefradil analogues and their use
AU2001235364A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Tetrahydronaphtalene derivatives and their use
BR0110079A (pt) * 2000-04-12 2002-12-31 Novartis Ag Combinação de compostos orgânicos
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
BR0108823A (pt) * 2000-12-29 2002-12-10 Osmotica Corp Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US20040266836A1 (en) * 2001-10-18 2004-12-30 Peter Buhlmayer Organic compounds
US20030180712A1 (en) * 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
WO2004110354A2 (fr) 2003-05-15 2004-12-23 Roskamp Research, Llc Methode de reduction d'un depot amyloide, neurotoxicite amyloide et microgliose
WO2004101535A1 (fr) * 2003-05-16 2004-11-25 Novartis Ag Composition pharmaceutique comportant du valsartan
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (fr) * 2003-11-25 2005-06-16 Novartis Ag Combinaison de composes organiques
WO2005070462A2 (fr) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprenant de la (s)-amlodipine et un bloqueur du recepteur de l'angiotensine, et leurs methodes d'utilisation
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
PT1874311E (pt) 2005-04-15 2011-11-25 Res & Innovation S P A Método para prevenir, retardar ou reverter a deposição anómala de amilóide
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
CA2626682A1 (fr) * 2005-11-08 2007-05-18 Novartis Ag Combinaison de composes organiques pour le traitement des maladies cardiovasculaires
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
ES2449594T3 (es) 2007-10-05 2014-03-20 Alzheimer's Institute Of America, Inc. Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina
CN101433536A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和沙坦类药物的治疗组合物
JP2011507973A (ja) * 2007-12-31 2011-03-10 ルピン・リミテッド アムロジピンとバルサルタンとの医薬組成物
US20100137403A1 (en) * 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
CA2832758C (fr) 2011-04-12 2015-12-15 Boryung Pharmaceutical Co., Ltd. Composition pharmaceutique antihypertensive
MX2014001556A (es) 2011-08-12 2014-03-31 Boehringer Ingelheim Vetmed Composicion farmaceutica de sabor enmascarado.
WO2013147137A1 (fr) * 2012-03-30 2013-10-03 味の素株式会社 Agent thérapeutique pour le traitement de l'insuffisance cardiaque
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
US20180071272A1 (en) * 2014-10-23 2018-03-15 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms
RU2616213C2 (ru) * 2015-07-10 2017-04-13 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
DK3368080T3 (da) * 2015-10-31 2023-06-12 Io Therapeutics Inc Behandling af nervesystemforstyrrelser ved anvendelse af kombinationer af RXR-agonister og thyreoideahormoner
CN105287550A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种缬沙坦/非洛地平复方制剂及其制备方法
IL297333A (en) * 2020-04-17 2022-12-01 Honeybrains Llc Preparations and methods for the treatment of neuropsychiatric disorders
US20240299405A1 (en) * 2020-05-28 2024-09-12 Hangzhou Qian Biotechnology Ltd Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399578A (en) * 1990-02-19 1995-03-21 Ciba-Geigy Corp Acyl compounds
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
WO1993017682A1 (fr) * 1992-03-04 1993-09-16 Abbott Laboratories Antagonistes des recepteurs de l'angiotensine ii
BR9306796A (pt) * 1992-07-27 1998-12-08 Pfizer Polipeptidio bloqueador dos canais de cálcio obtido a partir de agelenopsis aperta
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
CA2125251C (fr) * 1993-06-07 2005-04-26 Yoshiyuki Inada Composition pharmaceutique pour le traitement des affections mediees par l'angiotensine ii
ATE198551T1 (de) * 1993-07-15 2001-01-15 Hoffmann La Roche Pharmazeutische kombination, die einen hemmer des renin-angiotensin-systems und einen endothelin- antagonisten enthält
CZ268896A3 (en) * 1994-03-17 1997-03-12 Ciba Geigy Ag Pharmaceutical preparation for treating diabetic nephropathy and application of angiotensin ii antagonist for preparing thereof
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
EP1870098A3 (fr) 1998-07-10 2010-07-07 Novartis Ag Utilisation combinée de valsaratan et bloqueurs du canal de calcium à buts thérapeutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399578A (en) * 1990-02-19 1995-03-21 Ciba-Geigy Corp Acyl compounds
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
US5889020A (en) * 1994-02-08 1999-03-30 Ciba Vision Corporation Treatment of normotensive glaucoma with angiotensin II antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMERICAN HEART J. *
HUMAN HYPERTNSION *
PHARMACOL *
WORLD HEALTH ORGANISATION-INTERNATIONAL SOCIETY OF HYPERTENSION GUIDELINES FOR THE MANAGEMENT OF HYPERTENSION *

Also Published As

Publication number Publication date
KR20010079517A (ko) 2001-08-22
CA2678722A1 (fr) 2000-01-20
AU753486B2 (en) 2002-10-17
CA2336822C (fr) 2009-11-17
TR200100062T2 (tr) 2001-06-21
DE122007000055I1 (de) 2007-12-13
RU2012110522A (ru) 2013-09-27
SI1096932T1 (sl) 2008-04-30
RU2243768C2 (ru) 2005-01-10
BE2016C011I2 (fr) 2018-12-04
CN1733307A (zh) 2006-02-15
CY2007026I2 (el) 2009-11-04
SI2322174T1 (sl) 2015-12-31
CN1234357C (zh) 2006-01-04
PT1096932E (pt) 2007-09-21
DK1096932T3 (da) 2007-10-15
NO20010113D0 (no) 2001-01-08
KR20040078140A (ko) 2004-09-08
NL300800I2 (fr) 2016-07-27
WO2000002543A3 (fr) 2000-06-29
LU91358I2 (fr) 2007-11-06
HK1036758A1 (en) 2002-01-18
HK1152897A1 (en) 2012-03-16
SK312001A3 (en) 2001-06-11
BR9912021A (pt) 2001-04-03
RU2450813C2 (ru) 2012-05-20
NZ509260A (en) 2003-09-26
ES2289814T3 (es) 2008-02-01
CY1116770T1 (el) 2016-10-05
WO2000002543A2 (fr) 2000-01-20
HUP0102828A2 (hu) 2002-04-29
SK285863B6 (sk) 2007-10-04
IL213926A0 (en) 2011-07-31
CY2016006I2 (el) 2016-10-05
CZ304359B6 (cs) 2014-03-26
CY2007026I1 (el) 2009-11-04
ZA200100232B (en) 2002-04-09
EP1096932B1 (fr) 2007-08-29
DE69936992D1 (de) 2007-10-11
PL194604B1 (pl) 2007-06-29
FR16C0008I1 (fr) 2016-04-15
JP2002520274A (ja) 2002-07-09
EP1870098A2 (fr) 2007-12-26
NZ527598A (en) 2005-04-29
NO20010113L (no) 2001-03-09
NL300290I2 (nl) 2008-11-03
AU5034999A (en) 2000-02-01
LU92992I2 (fr) 2016-05-09
IL140665A (en) 2012-12-31
DK2322174T3 (en) 2015-10-12
PL345897A1 (en) 2002-01-14
CA2678722C (fr) 2013-08-27
EP2322174B1 (fr) 2015-09-23
ATE371448T1 (de) 2007-09-15
EP1096932A2 (fr) 2001-05-09
FR16C0008I2 (fr) 2018-06-08
ID27664A (id) 2001-04-19
EP2322174A3 (fr) 2011-07-27
ES2552639T3 (es) 2015-12-01
HU229383B1 (en) 2013-11-28
IL140665A0 (en) 2002-02-10
EP1870098A3 (fr) 2010-07-07
NO2012013I1 (no) 2012-07-30
KR100550167B1 (ko) 2006-02-08
NO331802B1 (no) 2012-04-10
PT2322174E (pt) 2015-10-27
CA2336822A1 (fr) 2000-01-20
CY2016006I1 (el) 2016-10-05
CN1312715A (zh) 2001-09-12
NO2012013I2 (no) 2014-10-27
CZ299429B6 (cs) 2008-07-23
CZ200187A3 (en) 2001-05-16
NL300290I1 (fr) 2007-11-01
EP2322174A2 (fr) 2011-05-18
HUP0102828A3 (en) 2002-11-28
CY1107779T1 (el) 2010-07-28
DE69936992T2 (de) 2008-03-06

Similar Documents

Publication Publication Date Title
FR16C0008I1 (fr)
BE2016C025I2 (fr)